TERN (Terns Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TERN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-05 | Heather D Turner | Director | D | — | — |
| 2026-05-05 | JEFFREY B KINDLER | Director | D | — | — |
| 2026-05-05 | Jill M. Quigley | Director | D | — | — |
| 2026-05-05 | DAVID A FELLOWS | Director | D | — | — |
| 2026-05-05 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | — |
| 2026-05-05 | Robert Azelby | Director | D | — | — |
| 2026-05-05 | Emil Kuriakose | Chief Medical Officer | MIXED | — | — |
| 2026-05-05 | Andrew Gengos | Chief Financial Officer | MIXED | — | — |
| 2026-05-05 | Radhika Tripuraneni | Director | D | — | — |
| 2026-04-02 | Emil Kuriakose | Chief Medical Officer | Sell | — | — |
| 2026-03-17 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | — |
| 2026-02-18 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | — |
| 2026-02-02 | Heather D Turner | Director | A | — | — |
| 2026-02-02 | Robert Azelby | Director | A | — | — |
| 2026-02-02 | Jill M. Quigley | Director | A | — | — |
| 2026-02-02 | DAVID A FELLOWS | Director | A | — | — |
| 2026-02-02 | Radhika Tripuraneni | Director | A | — | — |
| 2026-02-02 | JEFFREY B KINDLER | Director | A | — | — |
| 2026-01-16 | Andrew Gengos | Chief Financial Officer | A | — | — |
| 2026-01-16 | Emil Kuriakose | Chief Medical Officer | A | — | — |
| 2026-01-16 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | — |
| 2026-01-06 | Emil Kuriakose | Chief Medical Officer | Sell | — | — |
| 2026-01-06 | Amy L. Burroughs | Chief Executive Officer | MIXED | — | — |
| 2025-11-05 | Jill M. Quigley | Director | MIXED | — | — |
| 2025-10-02 | Emil Kuriakose | Chief Medical Officer | Sell | — | — |
| 2025-07-03 | Emil Kuriakose | Chief Medical Officer | Sell | — | — |
| 2025-06-30 | Andrew Gengos | Chief Financial Officer | Buy | — | — |
| 2025-06-25 | Amy L. Burroughs | Chief Executive Officer | Buy | — | — |
| 2025-06-16 | Andrew Gengos | Chief Financial Officer | Buy | — | — |
| 2025-06-12 | Jill M. Quigley | Director | A | — | — |
| 2025-06-12 | Hongbo Lu | Director | A | — | — |
| 2025-06-12 | JEFFREY B KINDLER | Director | A | — | — |
| 2025-06-12 | Radhika Tripuraneni | Director | A | — | — |
| 2025-06-12 | Heather D Turner | Director | A | — | — |
| 2025-06-12 | DAVID A FELLOWS | Director | A | — | — |
| 2025-04-02 | Emil Kuriakose | Chief Medical Officer | Sell | — | — |
| 2025-02-25 | Andrew Gengos | Chief Financial Officer | A | — | — |
| 2025-02-24 | Robert Azelby | Director | A | — | — |
| 2025-02-03 | Hongbo Lu | Director | A | — | — |
| 2025-02-03 | Radhika Tripuraneni | Director | A | — | — |
| 2025-02-03 | JEFFREY B KINDLER | Director | A | — | — |
| 2025-02-03 | Amy L. Burroughs | Chief Executive Officer | Buy | — | — |
| 2025-02-03 | Jill M. Quigley | Director | A | — | — |
| 2025-02-03 | DAVID A FELLOWS | Director | A | — | — |
| 2025-02-03 | Melita Sun Jung | Chief Business Officer | Buy | — | — |
| 2025-02-03 | Emil Kuriakose | Chief Medical Officer | A | — | — |
| 2025-01-06 | Jill M. Quigley | Director | Sell | — | — |
| 2025-01-06 | Emil Kuriakose | Chief Medical Officer | Sell | — | — |
| 2025-01-06 | Mark J. Vignola | Chief Financial Officer | Sell | — | — |
| 2024-12-16 | Emil Kuriakose | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,382,033 | — |
| — | Director | 1,973,881 | — |
| — | Director | 1,968,480 | — |
| — | Director | 1,516,481 | — |
| — | Director | 762,400 | — |
| — | Director | 755,635 | — |
| — | 10%+ Owner | 529,762 | — |
| — | Director | 476,190 | — |
| — | 10%+ Owner | 281,223 | — |
| — | 10%+ Owner | 281,223 | — |
| — | 10%+ Owner | 275,772 | — |
| — | COO and General Counsel | 91,940 | — |
| — | Chief Financial Officer | 83,811 | — |
| — | President, Head of R&D | 75,000 | — |
| — | Director | 24,520 | — |
| — | Chief Executive Officer | 9,770 | — |
| — | Chief Business Officer | 2,250 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TERN quote page; the site-wide leaderboard is on the insider transactions hub.